相关实验视频
Updated: Jul 15, 2025

10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.9K
设计一种微生物发酵功能化的酸盐微球,用于针对性释放5-ASA,使用纳米食纤维载体治疗炎症性肠病
Lei Qiu1, Renbin Shen1, Lei Wei1
1Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, 215002, Jiangsu, China.
Journal of nanobiotechnology
|September 23, 2023
概括
这项研究引入了一种新的水凝微球系统,用于炎症性肠病 (IBD) 治疗. 它结合了有益的细菌和纳米颗粒来控制药物释放并减少肠道炎症.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 炎症性肠病 (IBD) 由于粘液障碍,在向药物输送方面存在挑战.
- 目前用于IBD治疗的策略往往缺乏有效控制在炎症部位释放药物.
- 将治疗方法与有益的肠道微生物群结合在一起的联合递送系统正在成为有前途的方法.
研究的目的:
- 开发一种新的酸盐水凝微球系统,用于在炎症性肠病 (IBD) 中控制药物释放.
- 利用肠道微生物群发酵来增强药物输送和治疗疗效在炎症性肠部位.
- 研究工程纳米粒子和益生菌在IBD管理中的潜力.
主要方法:
- 酸盐水凝微球的设计封装Bifidobacterium (Bac) 和药物修饰的纳米级食纤维 (NDF).
- 在体外评估药物释放动力学和微生物发酵效应.
- 在慢性结肠炎小鼠模型中对系统有效性的体内评估.
主要成果:
- 经过NDF修改的水凝微球表明增强了短链脂肪酸 (SCFA) 生产.
- 在炎症性肠部位观察到显著的5-aminosalicylic 酸 (5-ASA) 提升释放.
- 该系统有效地改善了肠道炎症,并在大肠炎小鼠中调节了肠道微生物群组成.
结论:
- 基于微生物发酵的控制释放系统为IBD提供了一个新的治疗策略.
- 开发的水凝微球系统显示了向药物输送和IBD治疗中的益生菌效应的潜力.
- 这种方法解决了粘液屏障的挑战,并提高了药物在结肠中的生物可用性.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
164
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
164
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
348
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
348
Drugs for Treatment of Constipation-Predominant IBS
197
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
197
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
237
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
237
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145

